Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial
Jabbour SA et al. Diabetes Care 2018: dc180680. doi: 10.2337/dc18-0680
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.